Last updated on June 2018

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema


Brief description of study

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly allocated order. In Part 1, the dose of 750mg will be assessed relative to placebo in up to 36 patients. If this is shown to be effective, then a further 12 patients will be enrolled at a 500mg dose (Part 1), followed by a further 12 (if efficacy still shown) at a dose of 250mg (Part 3) to determine the minimum effective dose of BCX7353 compared to placebo for treating HAE attacks. Efficacy will be determined by subject diary entries completed at pre-defined times post-dose.

Clinical Study Identifier: NCT03240133

Contact Investigators or Research Sites near you

Start Over

Clinical Trials

Study Center
Graz, Austria
  Connect »

Clinical Trials

Study Center
Grenoble, France
  Connect »

Clinical Trials

Study Center
Berlin, Germany
  Connect »

Clinical Trials

Study Center
Budapest, Hungary
  Connect »

Clinical Trials

Study Center
Odense, Denmark
  Connect »

Clinical Trials

Study Center
Lille, France
  Connect »

Study Center

Study Center
Frankfurt, Germany
  Connect »

Clinical Trials

Study Center
Ashkelon, Israel
  Connect »

Clinical Trials

Study Center
Tel Aviv, Israel
  Connect »

Clinical Trials

Study Center
Skopje, Macedonia, The Former Yugoslav Republic of
  Connect »

PI

Study Center
Tel HaShomer, Israel
  Connect »

Clinical Trials

Study Center
Milano, Italy
  Connect »

Clinical Trials

Study center
Padova, Italy
  Connect »

Clinical Trials

Study Center
Salerno, Italy
  Connect »

Clinical Trials

Study Center
Kraków, Poland
  Connect »